Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Abstract: The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.

Abstract: Provided herein are methods, kits, systems, and compositions or liquid biopsy yield enhancement.

Abstract: An antibody or fragment thereof, against presenilin, and more specifically against the luminal loop 1 of presenilin, for use in the treatment of cancer, by way of administrating a therapeutically effective quantity of the antibody or a fragment thereof, or a pharmaceutical composition comprising thereof, to a subject who suffers from cancer.

Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Abstract: The present invention provides a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. According to the present invention, cancer (excluding castration-resistant prostate cancer) is detected by measuring the intact growth and differentiation factor (GDF15) propeptide level, the GDF15 propeptide fragment level, or the total of the intact GDF15 propeptide level and the GDF15 propeptide fragment level, in a sample. The above described method for detecting cancer includes a method for detecting one or more selected from the group consisting of stomach cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and esophageal cancer, and a method for distinguishing and detecting non-small cell lung cancer and small cell lung cancer. Further, a reagent for detecting cancer includes an antibody that specifically recognizes GDF15 propeptide.

Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.

Abstract: Provided is an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits a specific binding ability for mesothelin, and thus, may be useful for preventing or treating cancer in which mesothelin is overexpressed.

Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present invention provides methods of treating cancer by combination therapy with CDK4/6 inhibitors and immune checkpoint inhibition.

Abstract: The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

Abstract: Provided herein are methods for treating, inhibiting, reducing the likelihood of and/or reducing the severity of antibody-mediated rejection (ABMR) in a subject with organ transplantation, by selecting a subject that has undergone an organ transplant; and administering to the subject a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent to the subject after transplantation, or both before and after transplantation.

Abstract: A modified antibody that binds specifically to folate receptor alpha (FOLR1) and blocks the activity of FOLR1 with an increased binding affinity, an antigen-binding fragment thereof, a composition containing the antibody or fragment, and their uses are disclosed. The modified antibody or antigen-binding fragment thereof may be used for the prevention or treatment of cancer proliferative disorder associated with an increased FOR1 expression, and may also be used for diagnosis of the disease. The proliferative disorder may be cancer.

Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Abstract: This disclosure relates to diagnostic assays useful to detect a carcinoma from a sample and antibodies or binding fragments thereof useful in the diagnostic tests. In certain embodiments, this disclosure relates to antibodies or fragments that bind HCA, epiglycanin, and/or fragments thereof. In certain embodiments, this disclosure relates to anti-idiotypic antibodies or fragments that bind the variable regions of antibodies that bind HCA and/or epiglycanin.

Abstract: The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.

Abstract: A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.

Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.